Pirimat

Quick links to important sections

Pirimat

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pirimat

Quick Facts

Property Description
Active ingredient Chlorphenamine Maleate
Form Tablet, syrup, oral solution, injection
Pharmacological class First-generation Antihistamine
General purpose Relief from allergic discomfort
Origin Synthetic drug

What is Pirimat?

Pirimat is a single-ingredient, synthetic medication classified as a First-generation Antihistamine. Its primary role is to alleviate the symptoms stemming from allergic conditions and histamine-mediated responses throughout the body. The drug entity is a well-established compound, notably listed on the World Health Organization Model List of Essential Medicines for its critical therapeutic utility.


What Type of Medicine is Pirimat?

Pirimat contains the active ingredient Chlorphenamine Maleate, which is the precise chemical salt of the molecule Chlorphenamine utilized in pharmaceutical preparations. As a First-generation Antihistamine, it belongs to the Alkylamine derivative chemical group and is entirely a synthetic drug, produced by chemical processes. This classification is significant because this group of compounds is clinically recognized for its effects on the central nervous system, distinguishing it from newer, often non-sedating alternatives.


Composition and Available Forms of Chlorphenamine

The formulation of Pirimat is typically centered around the Chlorphenamine Maleate compound as the sole active component, defining it as a single-ingredient product. The active substance is incorporated into several dosage forms to facilitate different routes of administration, suitable for various patient groups. These forms include the familiar solid tablet, liquid preparations like the syrup or oral solution, and a sterile injection form designated for parenteral use. The liquid forms are often used in pediatric patient groups and may include specific flavors, positioning them distinctly in the marketplace.


General Purpose and High-Level Action

The overarching purpose of this medicine is to address the physical manifestations of hypersensitivity reactions and allergic conditions. It achieves this through a mechanism known as histamine H1-receptor blockade. By performing this high-level action, the drug effectively prevents the body's natural histamine, released during an allergic response, from fully binding to its target receptors, thereby lessening the intensity of symptoms. H1 receptor antagonists are utilized to alleviate symptoms like itching and sneezing caused by histamine release. This fundamental anti-allergic action is recognized for its utility in neutralizing allergic discomfort.

What side effects are possible with Pirimat?

Possible Side Effects and Safety Information

The safety profile of Pirimat (Chlorphenamine Maleate), a first-generation antihistamine, is defined by its effects on the central nervous system (CNS) and its anticholinergic properties, as documented in official regulatory labeling.


Adverse Reaction Classification

Side effects are classified by frequency and categorized by System-Organ Class (SOC).

Classification Examples of Reactions (SOC)
Very Common Sedation, Somnolence (Drowsiness) (Nervous System)
Common Dizziness, Headache, Dry Mouth, Nausea, Fatigue, Blurred Vision (Various SOCs)
Frequency Unknown Blood Dyscrasias, Cardiac Arrhythmias, Hepatitis, Anaphylaxis (Serious Reactions)

Serious Adverse Reactions

Official labeling documents the potential for serious, though generally rare, events. These include various blood dyscrasias (e.g., Haemolytic anaemia, Agranulocytosis) and severe hypersensitivity reactions such as Anaphylaxis and Angioedema.

Safety Considerations and Restrictions

Safety data specifies that certain populations may be more susceptible to adverse effects. Children and older adults are noted as being more likely to experience both the neurological anticholinergic effects and paradoxical excitation (e.g., restlessness, confusion). The sedative properties also necessitate a constraint regarding use, as the medication may cause psychomotor impairment that affects the ability to operate machinery or drive. Caution is advised in patients with pre-existing conditions such as glaucoma, epilepsy, or specific forms of cardiovascular disease and urinary retention.

Overdose and Emergency Response

Overdose and when to seek help

A suspected overdose of Pirimat (Chlorphenamine Maleate) necessitates seeking immediate medical attention or contacting a certified Poison Control Center right away, as officially documented in prescribing information. The clinical manifestations of overdose primarily involve severe effects on the Central Nervous System (CNS) and the cardiovascular system.

CNS presentations listed in regulatory labeling range from profound drowsiness, confusion, and ataxia to severe agitation, hallucinations, and generalized convulsions (seizures). Anticholinergic signs, such as dilated pupils (mydriasis), dry mouth, and urinary retention, are also commonly noted. Severe and life-threatening outcomes explicitly documented include cardiac arrhythmias, profound hypotension leading to cardiovascular collapse, and respiratory depression, which can progress to apnoea.

Urgent contact with emergency services is required for any severe symptoms, such as trouble breathing or seizures. Specific population notes state that children and the elderly are more susceptible to severe reactions, with children being more likely to experience paradoxical excitation and seizures. Management measures described in official documents are strictly symptomatic and supportive, focusing on constant cardiac monitoring and vital signs observation, as no specific antidote is known for this poisoning.

Therapeutic Uses of Pirimat

What Pirimat Treats: Main Uses and Benefits

Pirimat (Chlorphenamine Maleate) is used across several therapeutic domains primarily to provide symptomatic relief and manage the physical manifestations associated with symptoms that create noticeable physiological strain. Its use is focused on contexts where additional symptomatic support is needed to help ease the overall burden of acute or recurrent discomfort.

The medication is commonly used to help with conditions characterized by episodic or fluctuating symptom patterns, including allergic rhinitis (hay fever), urticaria (hives), and localized reactions to insect stings and bites. It helps address symptom clusters that may appear suddenly or fluctuate, such as persistent sneezing, runny nose (rhinorrhea), itchy eyes, and generalized pruritus (itching).

“Pirimat contributes to easing the overall symptom load during periods of heightened discomfort, which assists with maintaining functional stability.”

This short-term assistance is relevant in clinical settings marked by heightened patient distress, helping patients cope more steadily with difficult episodes.


Quick Fact: Relief for Allergic Discomfort

Symptom Domain Conditions Managed Primary Benefit
Nasal / Ocular Allergic Rhinitis, Hay Fever Helps manage sneezing and discharge
Dermal / Cutaneous Hives (Urticaria), Itching Supports the easing of physical discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information on Chlorpheniramine

Eligibility and Restrictions for Use

Who Can and Cannot Use Pirimat?

The eligibility for using Pirimat (Chlorphenamine Maleate) is strictly defined by regulatory documents, which categorize populations based on age, physiological status, and concurrent conditions.

Contraindicated Populations

Use of Pirimat is contraindicated and formally prohibited for patients with a known hypersensitivity to the active ingredient or any excipient. It must not be used by patients currently taking, or who have taken within the last 14 days, Monoamine Oxidase Inhibitors (MAOIs). Use is also contraindicated in newborns and premature infants, as well as patients presenting with narrow-angle glaucoma or urinary retention.

Age and Condition Restrictions

While generally used by adults and children over 12 years, the medicine is typically not recommended for children under 6 years of age in standard formulations. Older adults require cautious use due to heightened susceptibility to neurological effects. Safety for use during pregnancy and lactation (breastfeeding) has not been established; therefore, use is not recommended unless considered essential. Conditional use is required for populations with severe hepatic or renal impairment or conditions like prostatic hypertrophy.

What should I know about interactions with other medicines?

The interaction profile of Pirimat (Chlorphenamine Maleate) is primarily defined by documented pharmacodynamic effects and one formal contraindication, as stated in government regulatory labeling.

Interaction Scope

Detail Official Regulatory Information
Medicinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) Depressants, Other Anticholinergic Drugs, and Alcohol (Ethanol).
Specific interacting medicines (if explicitly listed): Phenytoin is listed as an interaction target.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic enhancement (additive CNS depression and anticholinergic effects); Metabolic inhibition (of Phenytoin hepatic clearance).
Timing-based interaction rules (if applicable): A 14-day washout period is mandated after stopping MAOI therapy before Pirimat may be administered.
Population-specific interaction notes (if applicable): The Elderly are noted to have increased susceptibility to the CNS depressant and anticholinergic interaction effects.

Interaction Classifications (High-Level)

Classification Detail Official Regulatory Classification
Interaction severity classification (as defined in official documents): Contraindicated Combination (MAOIs); Clinically Significant Interaction (CNS Depressants, Anticholinergics, Phenytoin).
Regulatory basis: FDA Prescribing Information and national SmPCs.
Interaction-context constraints: Combination with MAOIs requires a time interval constraint. Use with CNS depressants mandates caution or avoidance.

Resulting Interaction Structure

Official Interaction Statements:

  • Co-administration with all Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the risk of prolonged and intensified effects.
  • Concurrent use with Alcohol and other CNS Depressants results in additive CNS depressant effects.
  • Combining with Other Anticholinergic Drugs leads to additive anticholinergic effects.
  • Pirimat is documented to inhibit the hepatic metabolism of Phenytoin, resulting in an officially noted rise in Phenytoin plasma levels.

Connection to the overall interaction profile: The regulatory documentation defines Pirimat’s interaction structure by a strict prohibition against use with MAOIs, which requires a specific 14-day separation period. The profile is further characterized by pharmacodynamic potentiation with CNS depressants and anticholinergic medicines, alongside one documented metabolic interaction with Phenytoin that alters its exposure.

Mechanism of Action

How Pirimat Works

Pirimat engages specific biological mechanisms to influence systems associated with endogenous mediator release, exerting its effect primarily through two distinct pharmacodynamic domains.

Antagonism of Histamine H1 Receptors

Pirimat functions within domains involving receptor-mediated signaling by competitively binding to the Histamine H1 receptor (H1R), acting as an inverse agonist or neutral antagonist. This molecular interaction suppresses the signaling cascade typically initiated by histamine, a key inflammatory mediator released from mast cells and basophils. The resulting biochemical consequence is a reduction in downstream cellular signaling mediated by histamine's binding to the H1R, thereby modifying the overall G q-coupled pathway activity.


Modulation of Cholinergic Pathways

Additionally, the compound engages mechanisms regulating other neurotransmitter systems, exhibiting weak anticholinergic activity. This action involves blocking muscarinic acetylcholine receptors, modifying early molecular steps in processes regulated by the parasympathetic nervous system, conveying both central nervous system (CNS) and peripheral physiological effects.

Dosage and Administration Information

How to Use Pirimat (Chlorphenamine Maleate): Official Administration Guidelines

This section details the authorized use of Pirimat, focusing on administration procedures and dosing schedules.

Administration Routes and Forms

Pirimat is available for both oral and parenteral administration. Oral forms include immediate-release tablets (typically 4 mg), extended-release tablets, and oral solution/syrup (typically 2 mg/5 mL). The solution for injection (typically 10 mg/mL) is approved for administration via the Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) routes.

Standard Dosing Schedule

Age Group Standard Single Oral Dose Maximum Daily Dose (24 Hours)
Adults 4 mg every 4 to 6 hours 24 mg
Children 6–12 Years 2 mg every 4 to 6 hours 12 mg
Elderly Reduced dose often recommended May be limited to 12 mg

For the injection, the maximum adult dose is generally limited to 40 mg in 24 hours. Dosing for children under 6 years is generally not recommended or requires explicit professional guidance.

Procedural Instructions

Oral Administration: Immediate-release tablets must maintain a minimum dosing interval of 4 hours. The tablets can be taken with or without food. Liquid forms must be measured using a precise dosing device, not a standard household spoon.

Parenteral Administration: If the injection is administered intravenously (IV), it must be injected slowly over a period of one minute to mitigate risks of side effects. Small pediatric injectable doses may require dilution to ensure accuracy.

Recent Clinical Evidence

Pirimat: Recent Clinical Evidence

Pirimat is an investigational compound that has been the subject of clinical research, primarily focusing on its potential role in managing symptoms of Condition A. The research is conducted within the rigorous framework of regulatory standards, and findings are continuously reviewed to ensure accuracy and patient safety.


Overview of Clinical Trials

Research has examined the use of this drug for symptoms associated with Condition A. Studies have investigated whether the drug is associated with a change in pain scores and the timing of any observed effect. One study evaluated whether participants experienced a change in flare-up frequency after the first month of participation.

Studies included research into the drug's proposed pathway of action. Research has explored the connection between the proposed pathway of action and observations in clinical outcomes. Studies have investigated whether combining this treatment with lifestyle changes is associated with a favorable outcome.


Special Populations and Research Scope

Research has examined the use of this drug in individuals with a history of liver issues, documenting the population characteristics included in these studies. Studies have also been conducted to compare the effect of this drug and Drug Y on joint inflammation. The research evidence describes the population of patients who participated in the studies that have evaluated the drug.

Pharmacokinetic studies have been conducted to evaluate the potential for variation in administration schedules. Furthermore, research has explored the potential of the drug for long-term use, and data regarding the frequency of adverse events have been collected over that period, contributing to the overall understanding of the compound.

Frequently Asked Questions (FAQ)

Common questions about Pirimat (FAQ)

Q: How quickly does Pirimat start working after you take it?

Official pharmacological data indicates that the active ingredient in Pirimat is absorbed relatively slowly after an oral dose. While peak concentrations in the body are typically reached a few hours later, the initial onset of the anti-allergic effect may be noticed within approximately two hours of administration.


Q: Is it normal to feel a little dizzy when you first start taking Pirimat?

Official product information indicates that dizziness is a documented common side effect of Pirimat. Because the drug can affect the Central Nervous System (CNS), this feeling is a known and frequent reaction, especially when first starting treatment.


Q: How long does Pirimat stay in your system?

Studies on the elimination of the active ingredient show a wide range for its half-life, which is the time it takes for half the drug to be eliminated from the body. In adults, this half-life is reported to range from approximately 14 to 43 hours after a single dose.


Q: Can Pirimat cause stomach upset or nausea?

Regulatory documents list nausea as a common side effect of Pirimat. Additionally, due to the drug’s anticholinergic properties, it may also contribute to other gastrointestinal issues like dry mouth or constipation.


Q: How do you know if Pirimat is actually working for you?

Pirimat is prescribed for the temporary relief of specific symptoms related to allergies and the common cold. Effectiveness is generally associated with the temporary relief or reduction of symptoms such as a runny nose, sneezing, itching, or watery eyes, which are the main uses of the medicine.


Q: What are the non-medical ingredients in Pirimat tablets or capsules?

The official product information lists both active and inactive ingredients. In addition to the active drug, tablets and capsules typically contain non-medical ingredients (excipients) such as common fillers like corn starch, lactose anhydrous, magnesium stearate, and microcrystalline cellulose. The specific inactive ingredients may vary depending on the product form.


Q: Does Pirimat affect blood pressure or heart rate?

The regulatory label advises caution for patients with pre-existing cardiovascular conditions, noting that rare but serious cardiovascular effects, such as cardiac arrhythmias (irregular heart rhythms), have been reported.


Q: What is the typical duration of treatment with Pirimat?

Pirimat is generally intended for short-term use to relieve acute or temporary symptoms. The patient information generally advises limiting use to no more than 7 days continuously, unless otherwise directed by a healthcare professional.


Q: Is the research on Pirimat considered high quality?

The active ingredient in Pirimat is a long-established compound that has been subject to standard clinical trials and reviews under strict regulatory frameworks. It is also listed on the World Health Organization Model List of Essential Medicines for its therapeutic utility.


Q: What common over-the-counter products should be avoided while on Pirimat?

Regulatory documents indicate that concurrent use with other over-the-counter products that cause drowsiness, such as certain cold and flu remedies or pain relievers, should be done with caution. This is due to the risk of additive Central Nervous System (CNS) depressant effects.


Q: What should I do if I miss a dose of Pirimat?

General patient information outlines specific steps for a missed dose, which typically includes skipping the dose if it is near the time of the next scheduled dose. Users are advised to follow their specific instructions for dosage intervals.


Q: Is it okay to stop taking Pirimat suddenly, or should I taper off?

Due to its mechanism of action and typical short-term use for allergy symptoms, the medication is not usually associated with withdrawal symptoms that require tapering. Therefore, tapering off is not generally required.


Q: Is there a generic version of Pirimat available?

Yes, the active ingredient in Pirimat, Chlorphenamine Maleate, is a well-known compound. It is widely available as a generic drug marketed by multiple pharmaceutical companies.


Q: Are there any specific foods that interact with Pirimat?

The official regulatory label does not list any major specific food interactions. The medication can typically be taken with or without food.


Q: What happens if Pirimat is taken with too much caffeine?

Pirimat is known for causing sedation. Taking large amounts of caffeine (a CNS stimulant) may result in competing effects, possibly causing feelings of nervousness, jitters, or restlessness, or potentially lessening the sedative effect.


Q: What is the mechanism of action of Pirimat at a cellular level?

At the cellular level, Pirimat works by acting on the Histamine H1 receptor. It competitively binds to this receptor, which prevents histamine (the body's natural allergy chemical) from fully binding and triggering its effects.


Q: Is there a possibility of becoming dependent on Pirimat?

Pirimat is not classified as a controlled substance and is not generally associated with drug dependence, abuse, or addiction like some other classes of medications that act on the Central Nervous System.


Q: Does Pirimat interact with herbal supplements like St. John's Wort?

The official label does not specifically list interactions with St. John’s Wort. However, because Pirimat is processed by certain liver enzymes (CYP2D6), any herbal supplement that strongly affects these same enzymes may potentially cause an interaction. Specific concerns about herbal supplements should be directed to a healthcare provider.


Q: Are there any long-term studies about the effects of Pirimat?

Official regulatory guidance emphasizes that Pirimat is generally intended for short-term use. The labeling is not structured to provide specific information regarding continuous long-term use for common allergic conditions, although safety data may be collected over longer periods in some clinical settings.


Q: Does Pirimat affect sleep or cause insomnia?

Pirimat is well-known for causing sedation, which may aid sleep. However, the official adverse reaction data also notes that effects on the Central Nervous System can sometimes include paradoxical reactions such as agitation, nervousness, and sleeplessness (insomnia) in certain individuals.

How should Pirimat be stored and disposed of?

How to Store and Dispose of Pirimat?

Pirimat (Chlorphenamine Maleate) must be stored and handled according to regulatory requirements to ensure stability and safety. The official labeled requirements address specific temperature, container, and environmental protection rules.


Official Storage and Handling

Requirement Domain Official Regulatory Statement
Temperature Range Store at controlled room temperature (20 C to 25 C)
Protection Keep container tightly closed and protect from light
Handling Restriction Do not freeze liquid formulations (syrup, injection)
Container Rule Store product in the original container

Disposal and Child Safety

It is mandatory to keep Pirimat out of the sight and reach of children. Unused or expired medication must be disposed of properly by following local guidelines or utilizing a medicine take-back program. Official instructions state that the medicine should not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pirimat found in:

A-Z Index: